about
Infections caused by Scedosporium spp.Osteoarticular Infections Caused by Non-Aspergillus Filamentous Fungi in Adult and Pediatric Patients: A Systematic ReviewPearson syndrome in an infant heterozygous for C282Y allele of HFE geneSeroepidemiological study of pandemic influenza H1N1 following the 2009-2010 wave in Greece.Risk factors for nasopharyngeal carriage of drug-resistant Streptococcus pneumoniae: data from a nation-wide surveillance study in Greece.Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against AspergilluFungal DNA detected in blood samples of patients who received contaminated methylprednisolone injections reveals increased complexity of causative agents.Expression of genes encoding innate host defense molecules in normal human monocytes in response to Candida albicans.Interactions between human phagocytes and Candida albicans biofilms alone and in combination with antifungal agents.Caspofungin at catheter lock concentrations eradicates mature biofilms of Candida lusitaniae and Candida guilliermondii.Amphotericin B formulations exert additive antifungal activity in combination with pulmonary alveolar macrophages and polymorphonuclear leukocytes against Aspergillus fumigatusSerum and cerebrospinal fluid levels of colistin in pediatric patients.Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum.Micafungin in premature and non-premature infants: a systematic review of 9 clinical trials.Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation.Aspergillus osteomyelitis: epidemiology, clinical manifestations, management, and outcome.Rapid susceptibility testing of medically important zygomycetes by XTT assay.Functional genomics of innate host defense molecules in normal human monocytes in response to Aspergillus fumigatus.In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds.Candida tropicalis in a neonatal intensive care unit: epidemiologic and molecular analysis of an outbreak of infection with an uncommon neonatal pathogen.Activities of triazole-echinocandin combinations against Candida species in biofilms and as planktonic cells.Reply to "not over yet: fungal infections following methyl prednisolone injections smoulder on"Reply to "detection of multiple fungal species in blood samples by real-time PCR: an interpretative challenge".Cytokines in immunodeficient patients with invasive fungal infections: an emerging therapy.Immunomodulation of invasive fungal infections.In vitro interactions between farnesol and fluconazole, amphotericin B or micafungin against Candida albicans biofilms.Development of new strategies for early diagnosis of mucormycosis from bench to bedside.Synergistic interaction of the triple combination of amphotericin B, ciprofloxacin, and polymorphonuclear neutrophils against Aspergillus fumigatusOsteomyelitis due to Aspergillus spp. in patients with chronic granulomatous disease: comparison of Aspergillus nidulans and Aspergillus fumigatus.Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species.Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic modelFuture directions in mucormycosis research.Recombinant cytokines in augmentation and immunomodulation of host defenses against Candida spp.How Biofilms Evade Host Defenses.Biofilms and Antifungal Susceptibility Testing.Effects of fluconazole on the metabolomic profile of Candida albicans.Epidemiology, risk factors and outcome of Candida parapsilosis bloodstream infection in childrenCombination therapy for mucormycosis: why, what, and how?Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology.Micafungin: pharmacology, experimental therapeutics and clinical applications.
P50
Q24657691-52119255-3396-455B-B452-4E1FB61BDBEDQ26774766-3DE48FCA-3E1C-4F7C-BDFE-AF2F6E410877Q28248388-EA395650-F613-4F88-A2A4-78BE48443E0BQ30404938-69500C48-94F0-4BC3-9479-D7572AD2FFB2Q33488329-507F5510-C5DC-4330-939C-350831D54D21Q33517581-DEE47202-17F3-4309-BA8F-5EECAA6F8BFDQ33703345-992CB668-E22D-463B-9646-B465DAAC0EB7Q33788125-E3BAF69A-7000-4D96-B5F8-530CD9FA8B8CQ34024546-EEFEA5BD-9E01-4F34-9AC5-B96753702218Q34058104-CF89A05B-96E2-45B2-94A0-04BEF516A7FCQ34108392-A245EF1D-47CE-4CAE-A8EB-A7EC8C3150ACQ34108747-9016A37E-966D-4CE9-8E47-47FA22203EFDQ34109768-02A93AF4-E00A-4047-8E83-326BA4722794Q34337608-13651E36-5AEF-4A2C-BA65-5D3A9C20F60AQ34427584-5B8BB013-6BB7-499A-B3C3-6C5F9F04A19CQ34428225-B6BFDB26-F81D-48DC-A2AE-68E2A6E2E2F5Q34430832-A9C588D4-BD82-4F29-97B3-A6704889C786Q34492766-CB8D454B-A36B-4B75-BB09-0077C40A392AQ34596443-5BDF4652-2176-45A9-B551-4DDA8467B2E9Q34753481-BB34F117-5C1F-4D66-B629-3D804B618144Q34932922-E932EC1C-6EEA-46F9-A21F-EF2A6CAD5634Q35035907-F93CA492-B6B1-4105-B2D8-3E1AE874288CQ35035917-66314AD8-7D3D-41FF-BCD4-731C9571F30DQ35116259-2BBE8A2C-7462-49D4-BE0C-52A3CBE05CB5Q35129044-67411A83-4268-40E4-ABE6-00077FA5A84CQ35152853-2A900B1C-FF9C-40A6-B85A-F1133EEF32BEQ35491540-1DCFE354-60CE-4C81-A878-8F2DEA9F656BQ35598556-54D79DD2-A6A5-4481-AB47-9F86DDD2B0D8Q35633156-653731D6-B879-4DB6-98B7-30EF42757578Q35647724-C05ECBB9-017F-413D-92EE-B1009F7EE3ADQ35666627-FF3766C3-AFC0-4AD8-A1C8-2CADE3DE5420Q35672102-CC3E23DA-E4D1-4BCA-8EC7-7C15C928365CQ35674828-7BA253FC-ED25-414B-A8EB-528DCFA22237Q35694195-C54D5AC5-B7E2-49B9-AF11-0E1076328C37Q35827993-DA06A647-E08A-4287-BDA1-976A0CD93EF3Q35868887-51BCFE4E-2959-45A0-91DA-799D5D85498DQ35973408-E897A1A3-4DE1-443C-AE63-48C54CA9179CQ35974333-B672C00D-6BDA-4CFE-ADDB-C235D980A8C6Q36094939-B1AFFD07-13F4-4D52-A7C9-1C83DECB45D1Q36120798-3602749F-1FED-453E-88A2-57A029C22028
P50
description
researcher ORCID ID = 0000-0002-0202-364X
@en
name
Emmanuel Roilides
@ast
Emmanuel Roilides
@en
Emmanuel Roilides
@es
Emmanuel Roilides
@nl
type
label
Emmanuel Roilides
@ast
Emmanuel Roilides
@en
Emmanuel Roilides
@es
Emmanuel Roilides
@nl
prefLabel
Emmanuel Roilides
@ast
Emmanuel Roilides
@en
Emmanuel Roilides
@es
Emmanuel Roilides
@nl
P31
P496
0000-0002-0202-364X